Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Mims on FDA Approval of Ivosidenib in Patients With AML

July 20th 2018

Alice Mims, MD, medical oncologist, Department of Internal Medicine, Division of Hematology, Ohio State University Comprehensive Cancer Center, discusses the FDA approval of the IDH1m inhibitor ivosidenib for the treatment of patients with acute myeloid leukemia (AML).

Immunotherapy at the Forefront of ALL Treatment, Expert Says

July 20th 2018

Major advancements in immunotherapy are at the forefront of treatment for patients with acute lymphoblastic leukemia.

Dr. Roschewski Discusses DA-EPOCH-R in Burkitt Lymphoma

July 20th 2018

Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan; DA-EPOCH-R) in adult patients with Burkitt lymphoma.

Dr. Kahl Discusses Polatuzumab Vedotin in Lymphoma

July 20th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the antibody drug conjugate polatuzumab vedotin in lymphoma.

Bleomycin Linked to High Rate of Pulmonary Disorders among Patients with Hodgkin Lymphoma

July 20th 2018

A retrospective study of patients with Hodgkin lymphoma found high rates of sequelae including pulmonary events and cardiovascular disease following frontline treatment with chemotherapy including bleomycin.

Treatment Options for CD30-Positive PTCL Subtypes

July 19th 2018

Steven M. Horwitz, MD, discusses the best strategy for the treatment of CD30-positive peripheral T-cell lymphomas.

The Future of Myeloma Induction May Be Quadruplets

July 19th 2018

Sarah Holstein, MD, PhD, discusses new approaches to induction therapy for patients with myeloma.

Navigating the Toxicities of Novel-Novel Combinations in Lymphoma

July 18th 2018

Combinations of novel drugs in lymphomas have the potential to overcome resistance to therapy but come with sometimes unexpected adverse events that demand careful monitoring.

Kahl Shares Antibody-Drug Conjugate Updates in Lymphoma

July 18th 2018

With promising data of brentuximab vedotin and inotuzumab ozogamicin leading the way, antibody-drug conjugates are beginning to make a greater impact on the lymphoma treatment landscape.

Selinexor FDA Submission Started for Multiple Myeloma

July 18th 2018

A rolling submission of an FDA new drug application (NDA) has been submitted for selinexor for the treatment of patients with penta-refractory multiple myeloma.

Expert Highlights Potential of Moxetumomab Pasudotox in Hairy Cell Leukemia

July 18th 2018

Robert J. Kreitman, MD, discusses the potential of moxetumomab pasudotox as a treatment for patients with hairy cell leukemia.

Dr. Kambhampati on the Impact of Next-Generation Sequencing in AML

July 18th 2018

Suman Kambhampati, MD, co-medical director, Blood Cancer Program, Sarah Cannon Research Institute, discusses the impact of next-generation sequencing (NGS) in acute myeloid leukemia (AML).

Dr. Flinn on the RELEVANCE Trial in Follicular Lymphoma

July 17th 2018

Ian Flinn, MD, PhD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the RELEVANCE trial in follicular lymphoma.

Dr. Pinilla-Ibarz Discusses Advancements in CML

July 16th 2018

Javier A. Pinilla-Ibarz, MD, PhD senior member, Moffit Cancer Center, discusses the recent advances in chronic myeloid leukemia (CML). Pinilla-Ibarz says that he and colleagues do not expect much in the field after other recent advancements, but he is still surprised to see what is being concentrated on today.

Dr. Madduri on SWOG S0777 in Multiple Myeloma

July 16th 2018

Deepu Madduri, MD, assistant professor, Mount Sinai Hospital, discusses evidence supporting the use of a triplet regimen versus a doublet regimen in elderly and transplant ineligible patients with multiple myeloma.

Pembrolizumab Data Reviewed in Classical Hodgkin Lymphoma

July 15th 2018

George F. Geils, Jr, MD, discussed the clinical efficacy and adverse event management techniques for pembrolizumab as a treatment for patients with classical Hodgkin lymphoma.

CAR T-cell Therapies Offer Hope for DLBCL

July 15th 2018

Chimeric antigen receptor T-cell therapies have quickly moved from early phase clinical trials to FDA approval for diffuse large B-cell lymphoma, with research now exploring ways to shift these agents earlier in the treatment paradigm.

Expert Discusses the Discontinuation of TKIs in Treatment Landscape of CML

July 14th 2018

Gabriela S. Hobbs, MD, discusses how discontinuing tyrosine kinase inhibitors will change the treatment landscape and other strategies for treating patients with chronic myeloid leukemia.

Dr. Barrientos on the Challenges in CLL

July 14th 2018

Jacqueline D. Barrientos, MD, MS, CLL Research and Treatment Program, Northwell Health Systems, discusses the current challenges oncologists are faced with in the field of chronic lymphocytic leukemia.

Dr. Lesokhin Discusses Exciting Advances in Multiple Myeloma

July 14th 2018

Alexander M. Lesokhin, MD, assistant attending, Department of Medicine and Myeloma Service, Memorial Sloan Kettering Cancer Center, discusses some of the exciting advancements currently happening in the field of multiple myeloma.